Results 221 to 230 of about 305,628 (395)

Stillbirth in pregnancies with flat OGTT: Placental clues to occult maternal dysmetabolism

International Journal of Gynecology &Obstetrics, EarlyView.
Emma Bertucci, Alessandra Danieli, Francesco Ricciardiello, Isabella Neri, Francesca Monari, Alessandro D. Genazzani, Gaetano Bulfamante, Antonio La Marca, Laura Botticelli, Fabio Facchinetti, Laura Avagliano   +10 more
wiley   +1 more source

Safety of Baricitinib for the Treatment of Atopic Dermatitis in Adults Over a Median of 1.6 and up to 4.6 Years Treatment: Final Integrated Analysis of Eight Clinical Trials

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Baricitinib is a selective Janus kinase (JAK)1/JAK2 inhibitor approved in more than 70 countries for the treatment of moderate‐to‐severe atopic dermatitis (AD) in adults, and in over 30 countries for adolescents and children from age 2 years with moderate‐to‐severe AD, who are candidates for systemic therapy.
Antonio Costanzo, Antonio Torrelo, Eric L. Simpson, Marjolein De Bruin‐Weller, Diamant Thaçi, Norito Katoh, Silvia Sabatino, Andrew Buchanan, Kasia Morawska, Samuel Ogwu, Karen Denning, Jonathan I. Silverberg   +11 more
wiley   +1 more source

NAT10-Mediated ac4C-Modification Exacerbates Ferroptosis by Stabilizing HMOX1 in Deep Vein Thrombosis. [PDF]

Arterioscler Thromb Vasc Biol
Zhang Y, Zhang Z, Liu X, Chu C, Yu X, Han Q, Li W, Zhang T, Zu H, Fan N, Wei R, Shi F, Li F, Xu F, Wang B, Li X.   +15 more
europepmc   +1 more source

Characteristics of Adult Patients With Atopic Dermatitis Initiating Biologics and Janus Kinase Inhibitors in the CorEvitas Atopic Dermatitis Registry

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Biologics and Janus kinase inhibitors (JAKi) are two advanced systemic treatment options for patients with atopic dermatitis (AD). The decision to initiate one of these therapies is complex and may be driven by many factors.
Eric L. Simpson, Linda Stein Gold, Seemal R. Desai, Alexandra K. Golant, Douglas DiRuggiero, Christian Fenske, Yolanda Muñoz Maldonado, Alvin H. Li, Zach Dawson, Kaylee Ho, Kayla Callahan, Gaia Gallo, Jonathan I. Silverberg   +12 more
wiley   +1 more source

Direct Relationship Between Heparin Binding to Midkine and Pleiotrophin and the Development of Acute Deep Vein Thrombosis. [PDF]

Biomedicines
Aydin S, Polat İ, Tural K, Duger N, Ugur K, Sahin İ, Aydin S, Lee DY.   +7 more
europepmc   +1 more source

Multiple Deep Vein Thrombosis

Internal Medicine, 2016
Shumpei, Onishi, Toshihisa, Ichiba, Hiroshi, Naito   +2 more
openaire   +3 more sources

Granulomatous Panniculitis in a Patient Treated With Cemiplimab: Case Report and Literature Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Immune checkpoint inhibitors (ICIs) have become a cornerstone in the treatment of advanced malignancies by enhancing antitumor immunity, but they may also trigger a broad spectrum of immune‐related adverse events (irAEs) involving multiple organs.
B. Lada‐Colunga, J. L. Artola‐Igarza, N. Martinez‐Peña, I. Arevalo‐Ortega, J. Rodriguez‐Blandon, G. Cancho‐Galan, R. Izu‐Belloso   +6 more
wiley   +1 more source

Behçet's Disease as a Cause of Recurrent Deep Vein Thrombosis. [PDF]

Cureus
Rehman A, Monks W, Ahmed R, Marchbank N.
europepmc   +1 more source

Anticoagulation in patients with isolated distal deep vein thrombosis: a meta‐analysis

Journal of Thrombosis and Haemostasis, 2017
L. Franco, M. Giustozzi, G. Agnelli, C. Becattini   +3 more
semanticscholar   +1 more source

TET3‐Mediated m5C Modification of CCAT2 Accelerates Cardiac Microvascular Endothelial Cell Damage in Acute Coronary Syndrome

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Acute coronary syndrome (ACS) is a clinical syndrome involving myocardial ischemia. This study aimed to elucidate the mechanism of TET3 in ACS‐induced CMEC damage, thereby identifying a new target for ACS treatment. The expression of TET3 in ACS patients and healthy subjects was analyzed.
Jun‐Cheng Liu, Wen‐Juan Wang, Ting‐Ting Zhang, Qi‐Chong Yang, Haliminai Dilimulati, Song‐Tao An   +5 more
wiley   +1 more source